Machine signal
Active cluster sell — 8 distinct insiders, $37.9M, window ends Oct 16, 2026.
Figures computed from official regulatory filings — .
Analysttarget 29.81 USD (+22%) · consensus 4.56/5 · 8 buy · 1 hold · 0 sell
Ownershipinsiders 1.29% · institutions 99.15% · short 9.4% of float
In USD · as of Oct 19, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for Adaptive Biotechnologies Corp only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.
Market information source · Oct 19, 2026
Periods recorded in the consulted sources. These do not certify the legal dates of name changes.
SEC company identity · Oct 19, 2026
Open-market timeline · full history
8 buys962 sells— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details |
|---|---|---|---|---|
| RUBINSTEIN JULIE | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| RUBINSTEIN JULIE | Sell | $304.3K | SEC |
| RUBINSTEIN JULIE | Exercise | $144.2K | SEC |
| RUBINSTEIN JULIE | Sell | $131.7K | SEC |
| RUBINSTEIN JULIE | Sell | $7.6K | SEC |
| RUBINSTEIN JULIE | Exercise | $144.2K | SEC |
| RUBINSTEIN JULIE | Exercise | $144.2K | SEC |
| RUBINSTEIN JULIE | Sell | $173.4K | SEC |
| RUBINSTEIN JULIE | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| RUBINSTEIN JULIE | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| RUBINSTEIN JULIE | Sell | $280.4K | SEC |
| RUBINSTEIN JULIE | Exercise | $144.2K | SEC |
| RUBINSTEIN JULIE | Exercise | $144.2K | SEC |
| RUBINSTEIN JULIE | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| RUBINSTEIN JULIE | Sell | $303K | SEC |
| RUBINSTEIN JULIE | Exercise | $144.2K | SEC |
| RUBINSTEIN JULIE | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| RUBINSTEIN JULIE | Sell | $232.7K | SEC |
| RUBINSTEIN JULIE | Sell | $313.8K | SEC |
| RUBINSTEIN JULIE | Sell | $70.4K | SEC |
| RUBINSTEIN JULIE | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| RUBINSTEIN JULIE | Sell | $256.7K | SEC |
| RUBINSTEIN JULIE | Exercise | $144.2K | SEC |
| RUBINSTEIN JULIE | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| RUBINSTEIN JULIE | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |